New stem cell legislation ‘fails to address safety and efficacy concerns’ – The Pharma Letter (registration)
The Pharma Letter (registration) |
New stem cell legislation 'fails to address safety and efficacy concerns'
The Pharma Letter (registration) The legislation was proposed to the Senate in March by stroke survivor Senator Mark Kirk of Illinois and would require the US Food and Drug Administration (FDA) to create a way to approve adult stem cell treatments without the large and costly Phase … |
